Enhancing RECK Expression Through miR-21 Inhibition : A Promising Strategy for Bladder Carcinoma Control
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Bladder carcinoma (BC) is the tenth most frequent malignancy worldwide, with high morbidity and mortality rates. Despite recent treatment advances, high-grade BC and muscle-invasive BC present with significant progression and recurrence rates, urging the need for alternative treatments. The microRNA-21 (miR-21) has superexpression in many malignancies and is associated with cellular invasion and progression. One of its mechanisms of action is the regulation of RECK, a tumor suppressor gene responsible for inhibiting metalloproteinases, including MMP9. In a high-grade urothelial cancer cell line, we aimed to assess if miR-21 downregulation would promote RECK expression and decrease MMP9 expression. We also evaluated cellular migration and proliferation potential by inhibition of this pathway. In a T24 cell line, we inhibited miR-21 expression by transfection of a specific microRNA inhibitor (anti-miR-21). There were also control and scramble groups, the last with a negative microRNA transfected. After the procedure, we performed a genetic expression analysis of miR-21, RECK, and MMP9 through qPCR. Migration, proliferation, and protein expression were evaluated via wound healing assay, colony formation assay, flow cytometry, and immunofluorescence.After anti-miR-21 transfection, miR-21 expression decreased with RECK upregulation and MMP9 downregulation. The immunofluorescence assay showed a significant increase in RECK protein expression (p < 0.0001) and a decrease in MMP9 protein expression (p = 0.0101). The anti-miR-21 transfection significantly reduced cellular migration in the wound healing assay (p < 0.0001). Furthermore, in the colony formation assay, the anti-miR-21 group demonstrated reduced cellular proliferation (p = 0.0008), also revealed in the cell cycle analysis by flow cytometry (p = 0.0038). Our results corroborate the hypothesis that miR-21 is associated with BC cellular migration and proliferation, revealing its potential as a new effective treatment for this pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Biochemical genetics - (2024) vom: 24. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dos Santos, Paulo Rodolfo Moraes [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder cancer |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s10528-024-10714-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370116240 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370116240 | ||
| 003 | DE-627 | ||
| 005 | 20240324235553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10528-024-10714-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370116240 | ||
| 035 | |a (NLM)38522065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dos Santos, Paulo Rodolfo Moraes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing RECK Expression Through miR-21 Inhibition |b A Promising Strategy for Bladder Carcinoma Control |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Bladder carcinoma (BC) is the tenth most frequent malignancy worldwide, with high morbidity and mortality rates. Despite recent treatment advances, high-grade BC and muscle-invasive BC present with significant progression and recurrence rates, urging the need for alternative treatments. The microRNA-21 (miR-21) has superexpression in many malignancies and is associated with cellular invasion and progression. One of its mechanisms of action is the regulation of RECK, a tumor suppressor gene responsible for inhibiting metalloproteinases, including MMP9. In a high-grade urothelial cancer cell line, we aimed to assess if miR-21 downregulation would promote RECK expression and decrease MMP9 expression. We also evaluated cellular migration and proliferation potential by inhibition of this pathway. In a T24 cell line, we inhibited miR-21 expression by transfection of a specific microRNA inhibitor (anti-miR-21). There were also control and scramble groups, the last with a negative microRNA transfected. After the procedure, we performed a genetic expression analysis of miR-21, RECK, and MMP9 through qPCR. Migration, proliferation, and protein expression were evaluated via wound healing assay, colony formation assay, flow cytometry, and immunofluorescence.After anti-miR-21 transfection, miR-21 expression decreased with RECK upregulation and MMP9 downregulation. The immunofluorescence assay showed a significant increase in RECK protein expression (p < 0.0001) and a decrease in MMP9 protein expression (p = 0.0101). The anti-miR-21 transfection significantly reduced cellular migration in the wound healing assay (p < 0.0001). Furthermore, in the colony formation assay, the anti-miR-21 group demonstrated reduced cellular proliferation (p = 0.0008), also revealed in the cell cycle analysis by flow cytometry (p = 0.0038). Our results corroborate the hypothesis that miR-21 is associated with BC cellular migration and proliferation, revealing its potential as a new effective treatment for this pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a Disease progressions | |
| 650 | 4 | |a Metalloproteinases | |
| 650 | 4 | |a MicroRNA | |
| 650 | 4 | |a RECK | |
| 700 | 1 | |a da Silva Gomes, Paulo Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Romão, Poliana |e verfasserin |4 aut | |
| 700 | 1 | |a Maluf, Feres Camargo |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Vanessa Ribeiro |e verfasserin |4 aut | |
| 700 | 1 | |a Candido, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, Guilherme Lopes |e verfasserin |4 aut | |
| 700 | 1 | |a de Camargo, Juliana Alves |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Gabriel Arantes |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Iran |e verfasserin |4 aut | |
| 700 | 1 | |a Leite, Katia Ramos Moreira |e verfasserin |4 aut | |
| 700 | 1 | |a Nahas, William |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Sabrina T |e verfasserin |4 aut | |
| 700 | 1 | |a Pimenta, Ruan |e verfasserin |4 aut | |
| 700 | 1 | |a Viana, Nayara Izabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical genetics |d 1967 |g (2024) vom: 24. März |w (DE-627)NLM000013455 |x 1573-4927 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10528-024-10714-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 24 |c 03 | ||